Abstract: In a producing method of alcohols such as cyclohexanedimethanol, a benzyl ester is obtained, for example, by the reaction between a benzyl compound and carboxylic acid in the presence of oxygen and a catalyst including palladium, gold ultra fine particles, and at least one kind of element selected from the group consisting of Group IIA, IIIA, VIA, IIB, VB, and VIII of the periodic table, and alkali metal. The alcohols are produced by hydrogenating a benzene ring of the benzyl ester and then hydrolyzing the resultant esters. Alternatively, the benzyl ester is hydrolyzed to produce benzyl alcohols, and a benzene ring of the benzyl alcohols is hydrogenated to produce the alcohols.
Type:
Grant
Filed:
October 2, 2000
Date of Patent:
July 29, 2003
Assignee:
Nippon Shokubai Co., Ltd.
Inventors:
Yusei Nagamura, Yuuichi Satoh, Jun Tatsumi, Kunihiro Yamamura
Abstract: A process for separating ethylene glycol from its aqueous mixture with organic acids, salts and unidentified UV light absorbers, the process comprising the steps of
a) flashing the aqueous mixture under conditions effective to produce a bottom slurry containing the salts and an overhead aqueous fraction containing the ethylene glycol, the acids and the unidentified UV light absorbers;
b) passing the overhead aqueous fraction from step a) through at least one bed of ion exchange resin effective to produce a product stream having a reduced UV light absorbance; and
c) drying the product stream of step b) in a dehydrator.
Type:
Grant
Filed:
May 31, 2001
Date of Patent:
February 25, 2003
Assignee:
Shell Oil Company
Inventors:
Hendrikus Jacob Baars, Alouisius Nicolaas Rene Bos, Jelte Kars
Abstract: Administration of a nitrosating compound, such as nitroglycerin, nitric oxide, S-nitrosothiol, S-nitroso-protein, nitroprusside, sydnonimines, furoxans, nitrosonium salts, and related compounds is used for the treatment or prevention of disease states resulting from hyperhomocysteinemia. The disease states include vascular, ocular, skeletal, neurological, and cytotoxicity disorders. In addition, nitrosating compounds may also be administered for the treatment or prevention of disease states resulting from other sulfur-containing amino acids, such as cysteine.